Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study

2 novembre 2026 aggiornato da: Ruijin Hospital

Real-World Efficacy and Safety of Sevabertinib as Second-Line or Later-Line Therapy in Patients With HER2-Mutant Advanced Non-Small Cell Lung Cancer: An Observational, Bidirectional Cohort Study

This is a single-center, observational, bidirectional cohort study evaluating the real-world effectiveness, safety, and quality of life associated with sevabertinib in Chinese adults with HER2-mutant advanced non-small cell lung cancer receiving sevabertinib as second-line or later-line therapy. The study will include both retrospectively identified patients and prospectively enrolled patients. The primary objective is to evaluate real-world progression-free survival. Additional assessments include tumor response, overall survival, safety, and patient-reported quality of life.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Osservativo

Iscrizione (Stimato)

16

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Hainan
      • Qionghai, Hainan, Cina, 571400
        • Reclutamento
        • Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital)
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Adult Chinese patients with unresectable locally advanced or metastatic non-squamous NSCLC harboring a documented HER2 (ERBB2) TKD activating mutation who receive sevabertinib as second-line or later-line therapy in routine clinical practice. The study includes both retrospectively identified patients and prospectively enrolled patients.

Descrizione

Inclusion Criteria:

  1. Age ≥18 years at the index date.
  2. Unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
  3. Documented HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutation.
  4. Received at least one prior systemic therapy for advanced NSCLC. Prior HER2-targeted antibody-drug conjugate (ADC) therapy is permitted, whereas prior HER2-targeted tyrosine kinase inhibitor (TKI) therapy is not permitted.
  5. For retrospectively included participants, sufficient baseline clinical, treatment, and prior follow-up data are available.
  6. Sevabertinib treatment has been determined by the treating physician based on clinical practice, or the participant has already initiated sevabertinib at screening.

Exclusion Criteria:

  1. History of Grade 3 or higher interstitial lung disease (ILD), or evidence of any clinically active ILD.
  2. Uncontrolled comorbid diseases or conditions, including but not limited to decompensated respiratory, cardiac, hepatic, or renal disease; ongoing or active infection, including active clinical tuberculosis; renal transplantation; or psychiatric/social conditions that may limit study compliance.
  3. Unstable brain metastases.
  4. Inability to comply with the study for any reason.
  5. Receipt of another unapproved investigational drug or non-drug treatment within 30 days before the index date or during the observation period.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: OTHER

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Sevabertinib-Treated Cohort

Adult Chinese patients with HER2-mutant advanced non-small cell lung cancer receiving sevabertinib as second-line or later-line therapy in routine clinical practice. Treatment with sevabertinib is determined by the treating physician and is not assigned by the study protocol.

Sevabertinib is administered as part of routine clinical care, generally at a dose of 20 mg orally twice daily with food until disease progression or unacceptable toxicity, according to the treating physician's clinical judgment. Treatment is not assigned by the study protocol.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Real-World Progression-Free Survival (rwPFS)
Lasso di tempo: From the first dose of sevabertinib until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 12 months.

rwPFS is defined as the time from the first dose of sevabertinib to the first documented disease progression or death from any cause, whichever occurs first.

From the first dose of sevabertinib until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 12 months.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Investigator-Assessed Real-World Objective Response Rate (rwORR)
Lasso di tempo: From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.

rwORR is defined as the proportion of evaluable participants whose best overall response is complete response (CR) or partial response (PR), as assessed by the investigator according to RECIST version 1.1.

From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
Investigator-Assessed Real-World Disease Control Rate (rwDCR)
Lasso di tempo: From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.

rwDCR is defined as the proportion of evaluable participants who achieve CR, PR, or stable disease (SD). Confirmed and unconfirmed best overall responses will be analyzed separately.

From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
6-Month and 12-Month Progression-Free Survival Rates
Lasso di tempo: At 6 months and 12 months after the first dose of sevabertinib.

The probabilities of participants being alive and free from disease progression at 6 months and 12 months after the first dose of sevabertinib.

At 6 months and 12 months after the first dose of sevabertinib.
Incidence of Treatment-Related Adverse Events
Lasso di tempo: From the first dose of sevabertinib through the last available safety assessment, up to 12 months.

The incidence of treatment-related adverse events of any grade and Grade 3 or higher will be assessed. Adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 6.0.

From the first dose of sevabertinib through the last available safety assessment, up to 12 months.
Change From Baseline in EORTC QLQ-C30 Scores
Lasso di tempo: Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.

The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) assesses cancer-related quality of life. Scores for each scale range from 0 to 100. Higher functional and global health status/quality-of-life scores indicate better functioning or quality of life, whereas higher symptom scores indicate worse symptoms.

Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
Change From Baseline in NSCLC-SAQ Total Score
Lasso di tempo: Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.

The Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) assesses NSCLC-related symptoms. The total score ranges from 0 to 20, with higher scores indicating greater symptom severity.

Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
Change From Baseline in EQ-5D-5L Index Score
Lasso di tempo: Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.

The EuroQol 5-Dimension 5-Level (EQ-5D-5L) assesses overall health status across five dimensions. Using the Chinese value set, index scores range from -0.391 to 1.000, with higher scores indicating better health status.

Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

20 ottobre 2026

Completamento primario (Stimato)

30 settembre 2028

Completamento dello studio (Stimato)

30 settembre 2028

Date di iscrizione allo studio

Primo inviato

27 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 ottobre 2026

Primo Inserito (Effettivo)

19 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • RWS2026-003

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data (IPD) are not planned to be shared with external researchers because the study uses sensitive clinical data derived from medical records and follow-up. Study data are de-identified and managed under applicable confidentiality, privacy, and institutional data security requirements, with access restricted to authorized study personnel.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .